Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2009

View Archived Issues

Studies reveal contraceptive efficacy of estradiol valerate/dienogest

KDR-4, a VEGFR2 inhibitor, developed for local intravitreal delivery

Avila Therapeutics presents on Btk inhibitor AVL-291, pan-ErbB inhibitor CNX-222 at AACR

Intellikine describes dual mTORC1/2 inhibitor INK-128

Data from first-in-human trial of MK-0752 reported

DNA alkylating agent BO-1062 selected for further development

GlobeImmune and Celgene collaborate on targeted immunotherapy for cancer

COTI-2 plus Taxol superior to Taxol alone in animal cancer model

ERYtech initiates recruitment for phase II clinical trial of Graspa for ALL

Galapagos reports on activities during first quarter of 2009

SkyePharma presents report on activities during first quarter of 2009

Finland approves Ark's Cerepro for treatment on named-patient basis

Cadence submits NDA to FDA for Acetavance for acute pain and fever in adults and children

Regulus achieves initial milestone under microRNA collaboration with GSK

ThromboGenics presents update on activities

GE Healthcare describes novel agents for X-ray diagnosis

Suven Life Sciences claims novel 5-HT6 receptor ligands as anxiolytics

Merck & Co. presents novel JAK and PDK1 kinase inhibitors for cancer treatment

Novel cathepsin inhibitor VBY-129 developed by Virobay for the treatment of autoimmune diseases

Ark Therapeutics provides interim pipeline update

Can-Fite reports positive results from its phase II keratoconjunctivitis sicca trial

Peplin presents results for phase III PEP-005 trial in actinic keratosis

Phase IIb DCCR trial for hypertriglyceridemia meets endpoint

FDA releases clinical hold from Nile's CD-NP Program for heart failure

Sepracor withdraws marketing authorization application for Lunivia (eszopiclone)

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...